Interleukin 7 (II:7) is a 25-kD cytokine that was initially described as a pre-B cell growth factor. This cytokine has also been shown to have T cell proliferative and differentiation effects. In this report, we demonstrate that antitumor cytotoxic T lymphocytes (CTL) generated by secondary in vitro sensitization of draining lymph node cells in Ib7 are effective in treating 3-day syngeneic methylcholanthrene (MCA) sarcoma pulmonary metastases in mice. In vivo titrations comparing Ib7 to Ib2 antitumor CTL show that they have equivalent potency in adoptive immunotherapy. II+-7 antitumor CTL generated against MCA sarcomas of weak immunogeneity are also tumor specific in their in vivo efficacy. This study represents the first successful use of a cytokine other than IL-2 for the generation of cells with in vivo efficacy in cellular adoptive transfer.
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Interleukin 7 (II:7) is a 25-kD cytokine that was initially described as a pre-B cell growth factor. This cytokine has also been shown to have T cell proliferative and differentiation effects. In this report, we demonstrate that antitumor cytotoxic T lymphocytes (CTL) generated by secondary in vitro sensitization of draining lymph node cells in Ib7 are effective in treating 3-day syngeneic methylcholanthrene (MCA) sarcoma pulmonary metastases in mice. In vivo titrations comparing Ib7 to Ib2 antitumor CTL show that they have equivalent potency in adoptive immunotherapy. II+-7 antitumor CTL generated against MCA sarcomas of weak immunogeneity are also tumor specific in their in vivo efficacy. This study represents the first successful use of a cytokine other than IL-2 for the generation of cells with in vivo efficacy in cellular adoptive transfer.
G
eneration of antitumor cells with activity in vitro and therapeutic efficacy in vivo has been described with lymphokine-activated killer (LAK) t cells, tumor-infiltrating lymphocytes (TIL), and secondary in vitro sensitized CTL (1) . In all of these methods of effector cell generation for adoptive immunotherapy, II+-2 has played a necessary role in lymphocyte culture and as a supportive agent for the transferred cells in vivo. While I1..2 is of prime importance in the generation of antitumor cytotoxic T cells, further search has uncovered other cytokines with T cell-activating and -proliferative capacity, including I1+-4 (2, 3) and I1:6 (4, 5) .
Recently, after the identification of a soluble molecule with pre-B cell growth factor activity, IL-7 was cloned (6) (7) (8) and shown to promote the proliferation of murine thymocytes (9-11), mature T cells (12) (13) (14) , as well as the generation of lytic CTL with alloreactivity from thymocytes (15) . We have recently shown that II.-7 was capable of generating antitumor CTL with similar cytolytic activity and enhanced specificity in StCr release when compared to those generated with IL-2 (Jicha, D. L., S. Schwarz, J. J. MulE, and S. A. Rosenberg, manuscript submitted for publication). In this report, we now demonstrate the in vivo efficacy and specificity of IL-7-generated antitumor CTL in mice bearing tumor metastases and compare this efficacy to that of antitumor CTL generated in Ib2.
1Abbreviations used in this paper: DLN, draining lymph node; LAK, lymphokine-activated killer; MCA, methylcholanthrene; TIL, tumorinfiltrating lymphocytes. Tumors. The methylcholanthrene (MCA)-induced 203 and 205 tumors are weakly immunogenic fibrosarcomas of B6 origin maintained in vivo by subcutaneous passage in syngeneic mice. All tumors were used fresh and were prepared as described previously (16) .
Materials and Methods

M~
Cytokines. Purified human rib7 was a gift of Sterling Drug, Inc. (Malvern, PA). Two lots of IL-7 were used, one with a specific activity of 4.7 x 107 U/mg of protein and another with a specific activity of 5.6 x 107 U/mg, as determined by bioassay using the Ib7-dependent IxN/2b pre-B cell line (6) . Human rib2 was a gift of Cetus Corp. (Emeryvilh, CA). Lyophilized Ib2 was reconstituted in sterile water to 106 U/ml, as confirmed in a bioassay using Ib 2-dependent CTLL (17) .
Antitumor CTL Cultures. Popliteal draining lymph nodes (DLN) were removed in sterile conditions 7 d after footpad inoculation of B6 mice with 106 MCA 203 or 205 tumors in 0.05 ml. Singlecell suspensions were prepared by crushing the DLN with the blunt end of a syringe plunger and subsequent filtration through nylon mesh. Cultures were carried out in 8-ml, six-well plates (Costar, Cambridge, MA) with 4 x 10 s DLN/ml. DLN were cocultured with 2 x 10S/ml MCA 203 or 205 (as appropriate per footpad inoculation) previously irradiated with 2,000 rad. Cultures were generated in Ib7 (100 ng/ml), IL-2 (20 U/m1), Ib7 (100 ng/ml) plus Ib2 (20 U/ml), or no cytokine as noted. In all cases, cells were cultured for 11 d before use in adoptive transfer experiments.
AdoFtive ImmunotheraFy Models. B6 mice were injected intravenously, via lateral tail vein, with 5 x 10 s MCA 203 or 205 tumor ceUs in 1 ml of HBSS, to induce pulmonary metastases. On day 3 after delivery of tumor cells, therapeutic cells were injected intra-venously, via lateral tail vein, at varying doses as noted. On day 14-17 after initial tumor delivery, pulmonary metastases were enumerated as described previously (17) .
StatisticalAnalysis. Significant differences in the number of pulmonary metastases among groups were analyzed by the Wilcoxon rank sum test. Two-sided jv values are presented in all cases.
Results and Discussion
To test the in vivo efficacy of I1:7-generated antitumor CTL obtained from DLN, we used a 3-d pulmonary metastatic model with the syngeneic MCA 203 sarcoma. Cell cultures were established in complete media without added cytokine in parallel with I1:7, I1:2, and I1:7 plus I1:2-supplemented cultures. Antitumor CTL were delivered intravenously once followed by I1:2 10,000 U given twice daily for 5 d beginning immediately after adoptive cell transfer. As shown in Table 1 , I1:7 and I1:2 cultures were equally effective in eradicating metastatic disease at titrated cell doses. I1:7 plus I1:2 cultures were equivalent to or slightly poorer in eradicating metastatic disease than cells cultured in either cytokine alone. Importantly, cells cultured without a cytokine during secondary in vitro sensitization did not eradicate metastatic disease even at the highest dose (3 x 106) of cells delivered. In one of two experiments, a small but significant decrease below HBSS treatment controls was seen with 3 x 106 and 106 cells derived from cultures with no cytokine, but this was significantly less than the therapeutic effect obtained with I1:7 or II:2 antitumor CTL at the equivalent cell dose. Fresh DLN, directly harvested from mice 7 d after footpad inoculation with the syngeneic autologous MCA 203 tumor, also had no therapeutic effect in three of three experiments. This latter finding established the necessity of secondary in vitro sensitization for the generation of therapeutic effector cells.
Supportive cytokine treatment with I-L-2 in adoptive therapy with secondarily stimulated antitumor CTL has been shown to augment the efficacy of cells in vivo, generally twofold (16) . In adoptive immunotherapy with TIL, a three-to fivefold augmentation in efficacy has been reported (19). The effect of supportive I1:2 on I1:7 antitumor CTL was evaluated by comparing the effect of delivering I1:2 (60,000 U/dose) or HBSS intraperitoneally twice daily for 5 d after titrated cellular adoptive transfer with CTL generated from DLN. As shown in Table 2 , I1:2 augmented the efficacy of 11:7 and Ib2 antitumor CTL over HBSS in two of three experiments. I1,7 antitumor CTL delivered without cytokine support were as effective as those CTL generated with IL-2 in eradicating metastases. Overall, five comparisons of II,7 vs. II:2 antitumor CTL without supportive cytokine treatment showed them to be equivalent in antitumor CTL efticacy, and in one case, the I1,7 antitumor CTL were significantly better.
IL-7 was also tested as a supportive cytokine. The I1,7 dose used (20 #g/dose) matched the I1,2 dose of 60,000 U on the basis of the weight of the protein content of cytokine administered. IL-7 as a supportive cytokine for I1,2 antitumor CTL resulted in significantly less metastatic disease than HBSS control-treated groups in two of three experiments. In no case did I1,7 support of I1,7 antitumor CTL result in significantly better antitumor effects than was seen with HBSS administration (data not shown).
To determine the in vivo specificity of I1,7 antitumor CTL, cells generated against MCA 203 and 205 tumors were adoptively transferred in a 3-d pulmonary metastatic model with 10,000 U II.-2 administered intraperitoneally twice daily for five consecutive days. As shown in Table 3 , adoptively transferred cells effectively treated only the respective autologous tumor when tested in the crossover pattern. These results demonstrated the specificity of MCA 203 and 205 I1,7-generated antitumor CTL in vivo.
In this report, we studied the in vivo efhcacy of antitumor CTL generated with 11,7. Our findings now extend the mature T cell-activating effects of IL-7 (12-14; andJicha, D. L., S. Schwarz, J. J. Mul6, and S. A. Rosenberg, manuscript submitted for publication) to include the induction of antitumor effector cells with therapeutic efficacy in vivo. We demonstrate that I1,7-generated antitumor CTL are effective in treating 3-d pulmonary metastatic disease from syngeneic, autologous tumor. Further, cells generated in Ib7 are as po- To our knowledge, these results represent the first successful therapeutic adoptive transfer of cells grown in a cytokine other than I1:2. This work further suggests that II:7 may have an important role in adoptive immunotherapy.
